Genetic-Code Degeneracy and Biotechnology Patents

The genetic code is degenerate, meaning that most amino acids can be specified by more than one codon. As a result, many different DNA sequences can encode exactly the same protein. This feature of molecular biology has important implications for biotechnology patents because it affects claim scope, patent eligibility, and strategies for protecting engineered nucleic acids.

A claim directed to a specific nucleotide sequence literally covers only that sequence, and a competitor may attempt to design around the claim by altering nucleotides while producing an identical protein. For example, if a claimed invention is limited to a particular coding sequence, a third party may be able to substitute synonymous codons throughout the gene without changing a single amino acid in the resulting protein. The modified DNA sequence may fall outside the literal language of the claim even though the biological product remains unchanged. Although the doctrine of equivalents may sometimes be invoked by a patent owner, literal infringement is generally more straightforward to establish than infringement under the doctrine of equivalents.

Patent practitioners have long addressed this problem by considering claim formats that extend beyond a single nucleotide sequence. One common approach is to claim a nucleic acid by the protein that it encodes rather than by a particular DNA sequence. A claim directed to “a nucleic acid encoding Protein X,” for example, may encompass numerous synonymous coding sequences that produce the same protein. Such a claim can provide substantially broader protection than a claim limited to one particular nucleotide sequence.

Genetic-code degeneracy also plays an important role in codon optimization. Because multiple codons can encode the same amino acid, scientists can redesign a gene without changing the protein that it produces. Codon optimization is commonly used to improve expression of recombinant proteins in selected host cells. Codons that are rarely used in one organism may be replaced with codons preferred by another host, potentially increasing protein production. Other modifications may alter GC content, remove undesirable sequence motifs, improve mRNA stability, or facilitate manufacturing. The resulting DNA sequence may differ substantially from the naturally occurring gene while still producing the same protein.

These engineered sequences can be valuable from both a commercial and patenting perspective. Unlike a naturally occurring gene, a codon-optimized sequence is created through deliberate human intervention. The modified sequence may therefore constitute patent eligible subject matter, although the usual requirements of novelty, nonobviousness, adequate disclosure, and patent eligibility must still be satisfied. In many biotechnology programs, commercially important protection may reside not in the natural sequence, but in the engineered sequence actually used for recombinant production.

Patent eligibility adds another layer of complexity. Following the Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics, a naturally occurring DNA sequence generally does not become patent eligible merely because it has been isolated from its natural environment. Thus, a broad claim directed to nucleic acids encoding a naturally occurring protein may encounter eligibility concerns if the claim encompasses naturally occurring DNA sequences.

Claim breadth and patent eligibility are therefore separate issues. A claim may be commercially attractive precisely because it is broad, yet that same breadth may cause the claim to encompass subject matter falling within the product-of-nature exception to patent eligibility.

By contrast, a sequence containing deliberate substitutions, or an artificial expression construct, may possess structural characteristics that are markedly different from those of its naturally occurring counterpart. Such differences can be important to the patent-eligibility analysis. For that reason, biotechnology patent applications frequently include claims directed not only to coding sequences, but also to engineered variants, expression constructs, vectors, recombinant host cells, and methods of using those materials.

Broad claiming based on genetic-code degeneracy also raises issues under 35 U.S.C. § 112. A claim encompassing a large family of nucleic-acid sequences must still be adequately supported by the patent specification and satisfy the applicable written-description and enablement requirements. The fact that numerous sequences can encode the same protein does not, by itself, establish that every conceivable sequence can properly be claimed.

The practical lesson is that a nucleotide sequence disclosed by an inventor should rarely be considered in isolation. Because many different DNA sequences can encode the same protein, the patent practitioner should consider what family of synonymous sequences, engineered variants, expression constructs, host cells, and uses actually represents the commercial invention. At the same time, the claims must be drafted with attention to patent eligibility and the disclosure requirements of § 112. Genetic-code degeneracy thus creates both an opportunity for broader protection and a need for careful claim strategy.

Disclaimer: This piece is provided for general informational purposes only and does not constitute legal advice. Patent issues are often complex and highly fact-specific, and no one should act on general information of this kind without consulting qualified patent counsel regarding the particular circumstances involved.